Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II larynx-preservation study of radiotherapy plus cetuximab after induction TPF in resectable locally advanced laryngeal squamous cell carcinoma
2008-000332-40Phase 2Completed
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Mar 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, docetaxel, cisplatin and fluorouracil in laryngeal squamous cell carcinoma (LSCC), sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Primary endpoint: Laryngectomy-free disease-specific survival. Started Mar 2008; status: completed.
02
Drugs
cetuximabdocetaxelcisplatinfluorouracil
03
Conditions
laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on 2008-000332-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000332-40.